By Sam Jejurikar, MD, Board-Certified Plastic Surgeon, Dallas, TX
Semaglutide and tirzepatide have changed my practice more than any single technology in the past twenty years. Patients are walking into my Dallas office having lost 40, 60, sometimes 100 pounds without an operating room. That is a real medical win. But almost every one of them asks me the same question within the first five minutes: “Why does my skin look like this, and what can I do about it?”
This post is my honest, evidence-based answer. I’ll cover what these drugs actually do to skin, which procedures people end up needing, how GLP-1 use affects surgical safety and results, and, most importantly, what you can do right now to protect your outcome.
First, the short version
GLP-1 medications do not damage skin directly. What they do is produce fast, large weight loss, and the skin simply cannot keep up. The fat underneath deflates, a meaningful share of the weight lost is muscle rather than fat, and the collagen scaffolding in the skin, which was already stretched and remodeled by years of carrying extra weight, has limited ability to snap back. The result is the “Ozempic face,” “Ozempic body,” and “Ozempic breast” that patients describe. None of these are new problems. Bariatric surgeons have seen them for decades. What is new is the sheer number of people experiencing them at once.
What actually happens to skin during rapid weight loss
Skin is a living organ with a specific architecture. Its strength comes from thick, organized bundles of type I collagen in the dermis, and its snap comes from a network of elastic fibers woven through them. When someone carries significant extra weight for years, the dermis is mechanically stretched, and that stretch changes the tissue itself.
Histology studies from the bariatric surgery world are the best evidence we have here, because the mechanism of skin change is the same regardless of how the weight comes off. In one of the classic studies, Orpheu and colleagues compared abdominal skin from 40 women after massive weight loss to 40 never-obese controls and found a clear depletion of collagen while elastic fibers were preserved or even increased. A 2021 study by Rocha and colleagues went further and showed that after massive weight loss, thick well-organized collagen fibers are replaced by thin, disorganized ones, with an increase in elastic fiber density. In plain language, the skin becomes softer and floppier because the collagen framework that used to hold it taut has been thinned out and scrambled, and no amount of “elasticity” can compensate for that.
Now layer the GLP-1 effect on top of that. These medications cause weight loss that is both fast and profound. In the STEP 1 trial, semaglutide produced roughly 15 percent total body weight loss over 68 weeks, and tirzepatide in SURMOUNT-1 reached over 20 percent at the highest dose. Skin that would have had years to adapt to gradual weight loss instead has months. And critically, the DEXA substudies of these trials showed that a large fraction of what was lost was lean mass, not fat: roughly 40 percent of total weight loss with semaglutide and about 25 percent with tirzepatide. Muscle is part of what fills out the face, the arms, the buttocks and the thighs. When both the fat and the muscle beneath the skin shrink, the skin envelope looks even more redundant than the fat loss alone would predict.
A 2025 systematic review in Aesthetic Surgery Journal Open Forum pooled 23 studies on “Ozempic face” and reached the same conclusion I see clinically: the drugs do not selectively melt facial fat. They accelerate volume loss everywhere, and a thinner fat pad under skin that has lost its collagen support makes sagging obvious in the temples, cheeks, tear troughs and jawline. The review also noted that rapid nutrient depletion can impair skin barrier function, contributing to dryness and a dull, crepey texture that many patients report.
The procedures GLP-1 patients are actually asking for
The 2025 American Society of Plastic Surgeons statistics report is striking. Eighty-two percent of ASPS member surgeons reported consultation requests related to GLP-1 use last year. And while ASPS is careful to note that correlation is not causation, the procedures that grew fastest are exactly the ones that treat deflation and laxity: facial fat grafting up 39 percent, brow lifts up 29 percent, upper body lifts up 22 percent, arm lifts up 21 percent, neck lifts up 21 percent, thigh lifts up 20 percent, facelifts up 13 percent, and breast lifts up 8 percent.
In my own practice, GLP-1 patients tend to fall into a few categories.
The face. The “Ozempic face” is really a combination of volume loss and skin descent. For mild cases, particularly in younger patients, hyaluronic acid fillers and collagen-stimulating injectables can restore volume in the midface and temples. For patients with true skin excess along the jawline and neck, a deep plane facelift and neck lift, often combined with fat grafting to replace lost volume, gives a far more natural and durable result than filler alone. I’ve written before about why I prefer to restore structure rather than simply fill a face, and that philosophy applies doubly here.
The breasts. Breast tissue is largely fat, so significant weight loss deflates the breast, drops the nipple, and leaves loose, sometimes wrinkled skin. A recent Aesthetic Surgery Journal Open Forum review by Nahabedian and colleagues described “Ozempic breasts” in detail: severe ptosis, asymmetry, loss of upper pole fullness and lateral curvature. Depending on how much volume remains, treatment is a breast lift alone, a lift with an implant, or a lift with fat grafting. For many of my Dallas patients this is where Motiva implants, combined with a mastopexy, produce a natural, soft result without an overfilled look.
The trunk. This is where the most dramatic skin excess lives. A tummy tuck handles the front of the abdomen and tightens the underlying muscle wall that has often been stretched. Patients who have lost 75 pounds or more frequently need a circumferential body lift, which addresses the abdomen, flanks, back and buttocks in one operation. Liposuction is often a supporting player rather than the main event here, because the problem is skin, not fat. I cover the full range of options in my guide to body contouring after weight loss.
The arms and thighs. Brachioplasty and thigh lift are the procedures with the largest year-over-year growth for a reason. These are areas where nonsurgical tightening simply cannot remove several inches of redundant skin. The trade-off is a scar, and part of my job in consultation is to help each patient decide whether the improvement in contour is worth the scar for them.
Nonsurgical options. Radiofrequency microneedling, ultrasound-based tightening, and injectable biostimulators have a role for mild laxity or for patients who are not surgical candidates. I’m direct with patients about this: these devices can improve skin quality and produce modest tightening, but they do not remove skin. If you can grab a handful, you need surgery, not a device.
How GLP-1 use affects surgical safety and results
This is the part most blog posts skip, and it’s the part that matters most if you’re planning an operation.
Anesthesia and aspiration risk. GLP-1 medications slow gastric emptying. That is part of how they work, and it means food can still be sitting in the stomach hours after you’ve stopped eating, which raises the risk of aspiration under anesthesia. In 2024 the American Society of Anesthesiologists, together with four other societies, issued updated guidance. Most patients can now continue their medication, but those in the dose escalation phase, those with active nausea, vomiting or constipation, and those on high doses are at higher risk. For those patients we recommend a clear liquid diet for 24 hours before surgery, and many anesthesiologists will perform a bedside gastric ultrasound before inducing anesthesia. In my practice, we individualize this decision with the anesthesia team for every GLP-1 patient, and we will not proceed if there is any doubt.
Wound healing. The evidence here is reassuring but not settled. A 2025 propensity-matched study in Aesthetic Surgery Journal by Liang and colleagues compared body contouring outcomes in GLP-1 users versus non-users and found no meaningful difference in readmissions, wound dehiscence or seroma; GLP-1 users actually had lower rates of cellulitis, likely because of better blood sugar control. A 2026 meta-analysis of nearly 9,000 body contouring patients did find a higher rate of wound separation among GLP-1 users, about 5 percent versus 3 percent, but the authors acknowledged the signal was driven by a single large cohort and became non-significant on sensitivity analysis. My reading of the data is that the medication itself is probably not the problem. The nutritional state of the patient taking it very often is.
Nutrition and lean mass. Patients on GLP-1s eat far less, and what they eat is often not protein. Wounds are built from protein. A patient who arrives for a body lift with low albumin, low iron, low vitamin D, and 20 pounds of muscle loss is set up for delayed healing regardless of which medication got them there. This is the single most modifiable risk factor I see, and it’s why I check labs on every massive weight loss patient before surgery.
Weight stability and the durability of your result. Here is the hard truth about timing. A body lift or facelift is a snapshot of your body at the moment of surgery. If you lose another 20 pounds afterward, the skin will loosen again. If you regain 20 pounds, the tension and contour change. The breast literature is blunt about this: additional weight loss of more than 5 kg after breast surgery frequently requires revision. The regain data is just as important. In the STEP 1 extension, patients who stopped semaglutide regained roughly two-thirds of their lost weight within a year. In SURMOUNT-4, 82 percent of patients who stopped tirzepatide regained more than a quarter of what they had lost within a year. This is why I ask every GLP-1 patient the same question before scheduling surgery: what is your plan for this medication over the next two years? If the answer is “I’m not sure,” we are not ready to operate.
How to protect your skin and your surgical result
There is a lot patients can do, and most of it starts long before the consultation.
Slow down if you can. The faster the loss, the less time skin has to adapt. Losing one to two pounds a week is kinder to skin than losing four. Talk with your prescribing physician about dose titration that gets you to your goal without racing there.
Prioritize protein. Most obesity medicine guidelines recommend roughly 1.2 to 1.6 grams of protein per kilogram of goal body weight daily during GLP-1 treatment, which is far more than most patients on these drugs actually eat because their appetite is suppressed. Protein shakes are fine. Getting protein in is more important than how you get it.
Lift weights. Resistance training two to three times a week is the only intervention consistently shown to preserve lean mass during pharmacologic weight loss. It won’t tighten skin, but it rebuilds the muscle that fills the skin, and that matters most in the arms, buttocks and face.
Get your labs checked. Albumin, prealbumin, iron, ferritin, vitamin B12, vitamin D, and a full metabolic panel. If you’re deficient, correct it for at least eight to twelve weeks before any operation.
Hydrate and protect your skin. Well-hydrated skin with an intact barrier heals better and looks better. Daily moisturizer, sun protection, and, for the face, a topical retinoid to stimulate collagen production are inexpensive and evidence-based.
Don’t smoke, don’t vape. This applies to everyone, but nicotine plus massive weight loss plus a long incision is a combination that produces wound problems.
Reach a stable weight and stay there. I ask patients to be within a few pounds of the same weight for at least three months, and ideally six, before we operate. That stability should be at a weight you can realistically maintain, not a low point you hit before adjusting your dose.
Decide on your medication plan with your prescriber. Whether you stay on a maintenance dose, taper, or stop, the decision should be made deliberately and before surgery, not after.
Be honest with your surgeon. Tell us the medication, the dose, when you last took it, and any GI symptoms. This is a safety issue, not a judgment.
The bottom line
GLP-1 medications are one of the most important medical advances of my career, and I encourage patients who benefit from them. But the weight loss they produce is not the finish line. For many people, it reveals a skin envelope that needs surgical restoration, and the quality of that restoration depends on things you control: how fast you lose, how much protein you eat, whether you lift, whether you correct your deficiencies, and whether you commit to a stable weight before we operate.
If you’ve lost a significant amount of weight on semaglutide or tirzepatide and want an honest assessment of what your skin needs, I’d be glad to see you at my Dallas office. We’ll go through your goals, your medication plan, and your labs, and build a timeline that protects both your safety and your result.
Dr. Sam Jejurikar is a board-certified plastic surgeon in Dallas, Texas, recognized by Newsweek, Castle Connolly, and D Magazine among the top plastic surgeons in America. He co-hosts the Beauty and the Beasts podcast with Dr. Sal Pacella.
References
- Daneshgaran G, Shauly O, Gould DJ. “Ozempic Face” in Plastic Surgery: A Systematic Review of the Impact of GLP-1 Receptor Agonists on Facial Aesthetics. Aesthet Surg J Open Forum. 2025.
- American Society of Plastic Surgeons. 2025 Plastic Surgery Statistics Report and press release, “Lift Procedures Led Growth as Demand for Restoration Drove Plastic Surgery in 2025.”
- Orpheu SC, et al. Collagen and Elastic Content of Abdominal Skin After Surgical Weight Loss. Obes Surg. 2010;20:480-486.
- Rocha RI, et al. Skin Changes Due to Massive Weight Loss: Histological Changes and the Causes of the Limited Results of Contouring Surgeries. Obes Surg. 2021.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021, including DEXA substudy.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022, including DEXA substudy.
- Nahabedian MY, et al. GLP-1 Receptor Agonist-Associated Weight Loss and Aesthetic Breast Surgery. Aesthet Surg J Open Forum. 2026.
- Liang F, et al. Postoperative Outcomes in Body Contouring Procedures Following GLP-1 Receptor Agonist Use: A Propensity-Matched Analysis. Aesthet Surg J. 2025;45(5):501.
- Elegbede AI, et al. Safety of GLP-1 Receptor Agonists in Body Contouring Surgery: A Systematic Review and Meta-Analysis. BMC Plast Reconstr Surg. 2026.
- American Society of Anesthesiologists et al. Multi-Society Clinical Practice Guidance for the Safe Use of GLP-1 Receptor Agonists in the Perioperative Period. October 2024.
- Wilding JPH, et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension. Diabetes Obes Metab. 2022.
- Aronne LJ, et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
